{
  "id": 512,
  "text": "accessdata.fda.gov/drugsatfdadocs/label/2024/125514s147lbl.pdf hkiar maintenancetherapydosingschedules e These agents may be considered when cisplatin and carboplatin are unavailable.flfnotsedprevoustheseagentscanbesedasecond-ineoruequnt thrapyaslnicalyappropriat gAnFDA-approvedbiosimilaris an appropriatesubstitute forbevacizumab.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: accessdata.fda.gov/drugsatfdadocs/label/2024/125514s147lbl.pdf hkiar maintenancetherapydosingschedules e These agents may be considered when cisplatin and carboplatin are unavailable.flfnotsedprevoustheseagentscanbesedasecond-ineoruequnt thrapyaslnicalyappropriat gAnFDA-approvedbiosimilaris an appropriatesubstitute forbevacizumab.\n\n<question>: ",
  "ChatGPT_response_0": "当顺铂和卡铂不可用时，可以考虑使用这些药物作为第二线或经常治疗的情况包括但不限于：患者无法耐受顺铂和卡铂的副作用，患者出现对顺铂和卡铂的耐药性，或者顺铂和卡铂的治疗效果不佳。这些药物可能成为替代方案，以确保患者能够接受有效的治疗并提高治疗成功率。值得注意的是，在选择使用这些药物时，应该遵循临床指南和医疗专家的建议，确保合理和安全地应用药物治疗。",
  "query": "这些药物可能在顺铂和卡铂不可用时被考虑，请问在哪些情况下可以使用这些药物作为第二线或经常治疗？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 这些药物可能在顺铂和卡铂不可用时被考虑，请问在哪些情况下可以使用这些药物作为第二线或经常治疗？\n\n<reference text>: accessdata.fda.gov/drugsatfdadocs/label/2024/125514s147lbl.pdf hkiar maintenancetherapydosingschedules e These agents may be considered when cisplatin and carboplatin are unavailable.flfnotsedprevoustheseagentscanbesedasecond-ineoruequnt thrapyaslnicalyappropriat gAnFDA-approvedbiosimilaris an appropriatesubstitute forbevacizumab.\n\n<reply>: ",
  "response": "当顺铂和卡铂不可用时，可以考虑使用这些药物作为第二线或经常治疗的情况包括但不限于：患者无法耐受顺铂和卡铂的副作用，患者出现对顺铂和卡铂的耐药性，或者顺铂和卡铂的治疗效果不佳。这些药物可能成为替代方案，以确保患者能够接受有效的治疗并提高治疗成功率。值得注意的是，在选择使用这些药物时，应该遵循临床指南和医疗专家的建议，确保合理和安全地应用药物治疗。"
}